Streetbeat News

Analyst Ratings

CERE

Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Cerevel Therapeutics Hldg (NASDAQ:CERE) but lowers the price target from $42 to $38.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:11 pm

CDP

Raymond James analyst William Crow has maintained an Outperform rating on COPT Defense (NYSE:CDP) but lowered the price target from $28 to $27.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:10 pm

CDW

Morgan Stanley analyst Erik Woodring maintains an Overweight rating on CDW (NASDAQ:CDW) but lowers the price target from $230 to $216.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:10 pm

CHRW

Morgan Stanley analyst Ravi Shanker has maintained an 'Underweight' rating on C.H. Robinson Worldwide (NASDAQ:CHRW) and lowered the price target from $62 to $60.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:09 pm

EAT

Raymond James analyst Brian Vaccaro has maintained a Strong Buy rating on Brinker International (NYSE:EAT) and raised the price target from $40 to $42.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:08 pm

IDXX

Barclays has maintained an Overweight rating on IDEXX Laboratories and raised its price target from $590 to $592, leading to a rise in the company's shares.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:07 pm

EAT

Morgan Stanley analyst John Glass has maintained an Equal-Weight rating on Brinker International (NYSE:EAT) and raised the price target from $33 to $36.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:07 pm

BMRN

Morgan Stanley analyst Matthew Harrison has maintained an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but lowered the price target from $125 to $117.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:05 pm

AMWL

Morgan Stanley analyst Craig Hettenbach has maintained an Equal-Weight rating on American Well (NYSE:AMWL) and lowered the price target from $2.5 to $1.75.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:04 pm

BX

A significant bearish stance has been taken on Blackstone (NYSE:BX) by a large investor, as indicated by unusual options activity. The sentiment among these big-money traders is 30% bullish and 70% bearish. Whales have been targeting a price range from $65.0 to $130.0 for Blackstone over the last 3 months. The current price of BX is up 2.35% at $96.97. Major financial institutions have maintained their positive ratings on Blackstone, with price targets ranging from $105 to $120.

Portfolio Pulse from Benzinga Insights

November 02, 2023 | 4:02 pm